Podocytes of AT2 Receptor Knockout Mice Are Protected from Angiotensin II-Mediated RAGE Induction

Background/Aims: The interaction of ‘advanced glycation end products’ (AGEs) and their receptor ‘RAGE’ plays an important role in diabetic nephropathy. We have previously found that in cultured differentiated podocytes, angiotensin II (ANG II) induces RAGE expression via an AT2 receptor-mediated pathway. Methods: To further confirm our results in an in vivo study, AT2 receptor knockout mice (AT2–/–) and wild-type mice were infused with ANG II by osmotic minipumps for 14 days. Results: As shown by immunohistochemistry, ANG II treatment of wild-type animals (C57BL6) allowed a significantly increased RAGE expression in renal podocytes in comparison to sham-operated C57BL6 mice. In contrast, RAGE expression in podocytes of ANG II-treated knockout mice (AT2–/–) was only moderately higher than in control animals, but significantly lower than in ANG II-treated wild-type mice. For the AGE species NΕ-carboxymethyllysine, a similar immunohistochemical staining pattern was found. There was no significant change in glomerular AT1a receptor expression. However, no difference in RAGE mRNA expression could be found between ANG II-infused wild-type and AT2–/– animals by real-time PCR using whole kidney mRNA, presumably due to the low abundance of podocyte mRNA in these preparations. No effects were seen on glomerular apoptosis. Conclusion: These data support the fact that ANG II-mediated RAGE induction in podocytes occurs via AT2 receptors. The present findings may suggest that not all ANG II-mediated changes in diabetic nephropathy can be treated with AT1 receptor blockers.

[1]  Merlin C. Thomas,et al.  Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor , 2010, Diabetologia.

[2]  Samy Suissa,et al.  Renal and retinal effects of enalapril and losartan in type 1 diabetes. , 2009, The New England journal of medicine.

[3]  F. Thaiss,et al.  Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice. , 2009, Kidney international.

[4]  Hiroshi Yamamoto,et al.  Angiotensin II Upregulates RAGE Expression on Podocytes: Role of AT2 Receptors , 2009, American Journal of Nephrology.

[5]  V. D’Agati,et al.  RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. , 2008, Journal of the American Society of Nephrology : JASN.

[6]  R. Maas,et al.  Rapid development of severe end-organ damage in C57BL/6 mice by combining DOCA salt and angiotensin II. , 2008, Kidney international.

[7]  G. Münch,et al.  Induction of novel cytokines and chemokines by advanced glycation endproducts determined with a cytometric bead array. , 2008, Cytokine.

[8]  J. S. Kim,et al.  Activation of the renin-angiotensin system within podocytes in diabetes. , 2007, Kidney international.

[9]  G. Wolf,et al.  Renin-angiotensin-aldosterone system and progression of renal disease. , 2006, Journal of the American Society of Nephrology : JASN.

[10]  L. Hunsicker,et al.  The Advanced Glycation End Product Nε-Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension , 2006 .

[11]  T. Miyatsuka,et al.  Rapid Communication: Blockade of Angiotensin II Receptors Reduces the Expression of Receptors for Advanced Glycation End Products in Human Endothelial Cells , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[12]  Masayoshi Takeuchi,et al.  RAGE Control of Diabetic Nephropathy in a Mouse Model , 2006, Diabetes.

[13]  H. Pavenstädt,et al.  Functional expression of the renin-angiotensin system in human podocytes. , 2006, American journal of physiology. Renal physiology.

[14]  C. Flores,et al.  Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. , 2005, Kidney international. Supplement.

[15]  Merlin C. Thomas,et al.  Interactions between renin angiotensin system and advanced glycation in the kidney. , 2005, Journal of the American Society of Nephrology : JASN.

[16]  T. Imaizumi,et al.  Angiotensin II augments advanced glycation end product‐induced pericyte apoptosis through RAGE overexpression , 2005, FEBS letters.

[17]  E. Ritz,et al.  Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. , 2005, Kidney international.

[18]  R. Spurney,et al.  Characterization of angiotensin II-receptor subtypes in podocytes. , 2003, The Journal of laboratory and clinical medicine.

[19]  V. D’Agati,et al.  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.

[20]  H. Holthöfer,et al.  Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition , 2002, Diabetologia.

[21]  G. Wolf,et al.  The Renin-Angiotensin System and Progression of Renal Disease: From Hemodynamics to Cell Biology , 2002, Nephron Physiology.

[22]  F. Thaiss,et al.  Angiotensin II activates nuclear transcription factor-κB through AT1 and AT2 receptors11See Editorial by Luft, p. 2272. , 2002 .

[23]  F. Thaiss,et al.  Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. , 2002, Kidney international.

[24]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[25]  S. Takasawa,et al.  Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.

[26]  M. Cooper,et al.  Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade , 2001, Diabetologia.

[27]  V. D’Agati,et al.  Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. , 2000, Journal of the American Society of Nephrology : JASN.

[28]  A. Verkman,et al.  Analysis of organ physiology in transgenic mice. , 2000, American journal of physiology. Cell physiology.

[29]  Hiroshi Yamamoto,et al.  The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[30]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[31]  F. Thaiss,et al.  Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. , 1997, The Journal of clinical investigation.

[32]  Brian K. Kobilka,et al.  Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice , 1995, Nature.

[33]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[34]  W. Couser,et al.  Activation of a local tissue angiotensin system in podocytes by mechanical strain. , 2004, Kidney international.

[35]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy , 2002 .

[36]  G. Barsh,et al.  Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice , 1996, Nature.

[37]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.